Advanced Medical Optics (EYE) Granted FDA Premarket Approval of Healon D(R) Viscoelastic

October 7, 2008 8:21 AM EDT

Advanced Medical Optics, Inc. (NYSE: EYE) today announced the U.S. FDA has granted premarket approval of Healon D(R) viscoelastic, a clear dispersive ophthalmic viscosurgical device for use as a surgical aid in cataract extraction, intraocular lens implantation, corneal transplant, and glaucoma filtration surgery.

Healon D(R) OVD's formula provides exceptional clarity in the surgical field and a high degree of protection of corneal endothelial cells. Due to its low molecular weight, Healon D(R) OVD coats the cornea and remains in place throughout the entire surgical process. Its lower viscosity provides ideal lubrication of IOL insertion systems. Like all members of the Healon(R) family, Healon D(R) OVD is latex free, which means a safer environment for patients and physicians.

The FDA's approval of Healon D(R) OVD allows AMO to introduce for the first time, two new dual-pack ophthalmic viscosurgical systems (OVS) featuring Healon D(R) and Healon GV(R) OVDs as well as Healon D(R) and standard Healon(R) OVDs in convenient combination packs.

Advanced Medical Optics, Inc. engages in the development, manufacture, and marketing of medical devices for the eyes in the Americas, Europe, Africa, the Middle East, Japan, and Asia Pacific.

Related Categories

Corporate News
FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?